Optomed Q4: Solid basis for growth

Research Note

2021-02-19

07:00

Redeye maintains the base case of EUR 7.7 per share for Optomed after the Q4 report today. Despite the temporary revenue setback due to the covid-19 crisis making traditional sales models inefficient, we believe the company has laid down important building blocks for future growth. We expect results to be seen during 2021 and beyond.

GA

Gergana Almquist

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.